nodes	percent_of_prediction	percent_of_DWPC	metapath
Buprenorphine—ABCB1—peripheral nervous system neoplasm	0.212	1	CbGaD
Buprenorphine—CYP2C18—Tretinoin—peripheral nervous system neoplasm	0.09	0.152	CbGbCtD
Buprenorphine—CYP2A6—Tretinoin—peripheral nervous system neoplasm	0.0437	0.074	CbGbCtD
Buprenorphine—ABCG2—Topotecan—peripheral nervous system neoplasm	0.0435	0.0737	CbGbCtD
Buprenorphine—ABCG2—Dactinomycin—peripheral nervous system neoplasm	0.0302	0.0511	CbGbCtD
Buprenorphine—CYP3A7-CYP3A51P—Tretinoin—peripheral nervous system neoplasm	0.0299	0.0506	CbGbCtD
Buprenorphine—CYP3A7—Tretinoin—peripheral nervous system neoplasm	0.0299	0.0506	CbGbCtD
Buprenorphine—CYP3A5—Tretinoin—peripheral nervous system neoplasm	0.0224	0.038	CbGbCtD
Buprenorphine—CYP2C8—Tretinoin—peripheral nervous system neoplasm	0.0216	0.0365	CbGbCtD
Buprenorphine—ABCG2—Vincristine—peripheral nervous system neoplasm	0.0186	0.0315	CbGbCtD
Buprenorphine—CYP1A2—Alitretinoin—peripheral nervous system neoplasm	0.0179	0.0304	CbGbCtD
Buprenorphine—ABCG2—Cisplatin—peripheral nervous system neoplasm	0.0173	0.0293	CbGbCtD
Buprenorphine—ABCG2—Etoposide—peripheral nervous system neoplasm	0.017	0.0288	CbGbCtD
Buprenorphine—ABCB1—Topotecan—peripheral nervous system neoplasm	0.0157	0.0266	CbGbCtD
Buprenorphine—ABCB1—Alitretinoin—peripheral nervous system neoplasm	0.0157	0.0266	CbGbCtD
Buprenorphine—CYP2C9—Tretinoin—peripheral nervous system neoplasm	0.015	0.0255	CbGbCtD
Buprenorphine—CYP1A2—Dacarbazine—peripheral nervous system neoplasm	0.0143	0.0243	CbGbCtD
Buprenorphine—CYP3A7-CYP3A51P—Vincristine—peripheral nervous system neoplasm	0.0137	0.0232	CbGbCtD
Buprenorphine—CYP3A7—Vincristine—peripheral nervous system neoplasm	0.0137	0.0232	CbGbCtD
Buprenorphine—ABCG2—Doxorubicin—peripheral nervous system neoplasm	0.0116	0.0197	CbGbCtD
Buprenorphine—ABCB1—Dactinomycin—peripheral nervous system neoplasm	0.0109	0.0184	CbGbCtD
Buprenorphine—CYP3A5—Vincristine—peripheral nervous system neoplasm	0.0103	0.0174	CbGbCtD
Buprenorphine—CYP3A5—Etoposide—peripheral nervous system neoplasm	0.00943	0.016	CbGbCtD
Buprenorphine—CYP3A4—Topotecan—peripheral nervous system neoplasm	0.0094	0.0159	CbGbCtD
Buprenorphine—CYP2C8—Etoposide—peripheral nervous system neoplasm	0.00907	0.0154	CbGbCtD
Buprenorphine—CYP3A4—Tretinoin—peripheral nervous system neoplasm	0.00874	0.0148	CbGbCtD
Buprenorphine—CYP1A2—Etoposide—peripheral nervous system neoplasm	0.00702	0.0119	CbGbCtD
Buprenorphine—ABCB1—Vincristine—peripheral nervous system neoplasm	0.0067	0.0113	CbGbCtD
Buprenorphine—CYP2C9—Cisplatin—peripheral nervous system neoplasm	0.00644	0.0109	CbGbCtD
Buprenorphine—ABCB1—Cisplatin—peripheral nervous system neoplasm	0.00625	0.0106	CbGbCtD
Buprenorphine—ABCB1—Etoposide—peripheral nervous system neoplasm	0.00614	0.0104	CbGbCtD
Buprenorphine—ABCB1—Doxorubicin—peripheral nervous system neoplasm	0.00419	0.00709	CbGbCtD
Buprenorphine—CYP3A4—Vincristine—peripheral nervous system neoplasm	0.00401	0.0068	CbGbCtD
Buprenorphine—CYP2D6—Doxorubicin—peripheral nervous system neoplasm	0.00395	0.00668	CbGbCtD
Buprenorphine—CYP3A4—Etoposide—peripheral nervous system neoplasm	0.00368	0.00623	CbGbCtD
Buprenorphine—CYP3A4—Doxorubicin—peripheral nervous system neoplasm	0.00251	0.00425	CbGbCtD
Buprenorphine—Naltrexone—ABCB1—peripheral nervous system neoplasm	0.000285	0.578	CrCbGaD
Buprenorphine—Naloxone—ABCB1—peripheral nervous system neoplasm	0.000208	0.422	CrCbGaD
Buprenorphine—Anorexia—Etoposide—peripheral nervous system neoplasm	9.14e-05	0.000487	CcSEcCtD
Buprenorphine—Decreased appetite—Cisplatin—peripheral nervous system neoplasm	9.1e-05	0.000485	CcSEcCtD
Buprenorphine—Bronchitis—Epirubicin—peripheral nervous system neoplasm	9.09e-05	0.000485	CcSEcCtD
Buprenorphine—Diarrhoea—Dactinomycin—peripheral nervous system neoplasm	9.07e-05	0.000483	CcSEcCtD
Buprenorphine—Hypersensitivity—Alitretinoin—peripheral nervous system neoplasm	9.05e-05	0.000482	CcSEcCtD
Buprenorphine—Nasopharyngitis—Doxorubicin—peripheral nervous system neoplasm	9.05e-05	0.000482	CcSEcCtD
Buprenorphine—Gastrointestinal disorder—Cisplatin—peripheral nervous system neoplasm	9.04e-05	0.000482	CcSEcCtD
Buprenorphine—Hypotension—Etoposide—peripheral nervous system neoplasm	8.96e-05	0.000478	CcSEcCtD
Buprenorphine—Pain—Cisplatin—peripheral nervous system neoplasm	8.95e-05	0.000477	CcSEcCtD
Buprenorphine—Alanine aminotransferase increased—Doxorubicin—peripheral nervous system neoplasm	8.93e-05	0.000476	CcSEcCtD
Buprenorphine—Muscular weakness—Doxorubicin—peripheral nervous system neoplasm	8.93e-05	0.000476	CcSEcCtD
Buprenorphine—Asthenia—Alitretinoin—peripheral nervous system neoplasm	8.82e-05	0.00047	CcSEcCtD
Buprenorphine—Abdominal distension—Doxorubicin—peripheral nervous system neoplasm	8.81e-05	0.000469	CcSEcCtD
Buprenorphine—Upper respiratory tract infection—Epirubicin—peripheral nervous system neoplasm	8.79e-05	0.000468	CcSEcCtD
Buprenorphine—Asthma—Doxorubicin—peripheral nervous system neoplasm	8.75e-05	0.000466	CcSEcCtD
Buprenorphine—Influenza—Doxorubicin—peripheral nervous system neoplasm	8.75e-05	0.000466	CcSEcCtD
Buprenorphine—Dysphagia—Doxorubicin—peripheral nervous system neoplasm	8.75e-05	0.000466	CcSEcCtD
Buprenorphine—Hypersensitivity—Vincristine—peripheral nervous system neoplasm	8.72e-05	0.000465	CcSEcCtD
Buprenorphine—Pruritus—Alitretinoin—peripheral nervous system neoplasm	8.69e-05	0.000463	CcSEcCtD
Buprenorphine—Feeling abnormal—Cisplatin—peripheral nervous system neoplasm	8.63e-05	0.00046	CcSEcCtD
Buprenorphine—Paraesthesia—Etoposide—peripheral nervous system neoplasm	8.61e-05	0.000459	CcSEcCtD
Buprenorphine—Weight decreased—Epirubicin—peripheral nervous system neoplasm	8.55e-05	0.000456	CcSEcCtD
Buprenorphine—Dyspnoea—Etoposide—peripheral nervous system neoplasm	8.55e-05	0.000456	CcSEcCtD
Buprenorphine—Somnolence—Etoposide—peripheral nervous system neoplasm	8.53e-05	0.000454	CcSEcCtD
Buprenorphine—Angina pectoris—Doxorubicin—peripheral nervous system neoplasm	8.52e-05	0.000454	CcSEcCtD
Buprenorphine—Asthenia—Vincristine—peripheral nervous system neoplasm	8.49e-05	0.000453	CcSEcCtD
Buprenorphine—Infestation NOS—Epirubicin—peripheral nervous system neoplasm	8.43e-05	0.000449	CcSEcCtD
Buprenorphine—Infestation—Epirubicin—peripheral nervous system neoplasm	8.43e-05	0.000449	CcSEcCtD
Buprenorphine—Vomiting—Dactinomycin—peripheral nervous system neoplasm	8.43e-05	0.000449	CcSEcCtD
Buprenorphine—Bronchitis—Doxorubicin—peripheral nervous system neoplasm	8.41e-05	0.000448	CcSEcCtD
Buprenorphine—Diarrhoea—Alitretinoin—peripheral nervous system neoplasm	8.41e-05	0.000448	CcSEcCtD
Buprenorphine—Rash—Dactinomycin—peripheral nervous system neoplasm	8.36e-05	0.000445	CcSEcCtD
Buprenorphine—Decreased appetite—Etoposide—peripheral nervous system neoplasm	8.34e-05	0.000444	CcSEcCtD
Buprenorphine—Gastrointestinal disorder—Etoposide—peripheral nervous system neoplasm	8.28e-05	0.000441	CcSEcCtD
Buprenorphine—Body temperature increased—Cisplatin—peripheral nervous system neoplasm	8.28e-05	0.000441	CcSEcCtD
Buprenorphine—Fatigue—Etoposide—peripheral nervous system neoplasm	8.27e-05	0.000441	CcSEcCtD
Buprenorphine—Pain—Etoposide—peripheral nervous system neoplasm	8.2e-05	0.000437	CcSEcCtD
Buprenorphine—Constipation—Etoposide—peripheral nervous system neoplasm	8.2e-05	0.000437	CcSEcCtD
Buprenorphine—Urinary tract infection—Epirubicin—peripheral nervous system neoplasm	8.19e-05	0.000437	CcSEcCtD
Buprenorphine—Conjunctivitis—Epirubicin—peripheral nervous system neoplasm	8.19e-05	0.000437	CcSEcCtD
Buprenorphine—Upper respiratory tract infection—Doxorubicin—peripheral nervous system neoplasm	8.13e-05	0.000433	CcSEcCtD
Buprenorphine—Dizziness—Alitretinoin—peripheral nervous system neoplasm	8.13e-05	0.000433	CcSEcCtD
Buprenorphine—Diarrhoea—Vincristine—peripheral nervous system neoplasm	8.1e-05	0.000432	CcSEcCtD
Buprenorphine—Sweating—Epirubicin—peripheral nervous system neoplasm	8.08e-05	0.000431	CcSEcCtD
Buprenorphine—Hepatobiliary disease—Epirubicin—peripheral nervous system neoplasm	7.97e-05	0.000425	CcSEcCtD
Buprenorphine—Weight decreased—Doxorubicin—peripheral nervous system neoplasm	7.91e-05	0.000422	CcSEcCtD
Buprenorphine—Sinusitis—Epirubicin—peripheral nervous system neoplasm	7.91e-05	0.000422	CcSEcCtD
Buprenorphine—Feeling abnormal—Etoposide—peripheral nervous system neoplasm	7.9e-05	0.000421	CcSEcCtD
Buprenorphine—Nausea—Dactinomycin—peripheral nervous system neoplasm	7.87e-05	0.00042	CcSEcCtD
Buprenorphine—Gastrointestinal pain—Etoposide—peripheral nervous system neoplasm	7.84e-05	0.000418	CcSEcCtD
Buprenorphine—Dizziness—Vincristine—peripheral nervous system neoplasm	7.83e-05	0.000417	CcSEcCtD
Buprenorphine—Vomiting—Alitretinoin—peripheral nervous system neoplasm	7.81e-05	0.000416	CcSEcCtD
Buprenorphine—Infestation—Doxorubicin—peripheral nervous system neoplasm	7.8e-05	0.000416	CcSEcCtD
Buprenorphine—Infestation NOS—Doxorubicin—peripheral nervous system neoplasm	7.8e-05	0.000416	CcSEcCtD
Buprenorphine—Rash—Alitretinoin—peripheral nervous system neoplasm	7.75e-05	0.000413	CcSEcCtD
Buprenorphine—Dermatitis—Alitretinoin—peripheral nervous system neoplasm	7.74e-05	0.000413	CcSEcCtD
Buprenorphine—Hypersensitivity—Cisplatin—peripheral nervous system neoplasm	7.71e-05	0.000411	CcSEcCtD
Buprenorphine—Bradycardia—Epirubicin—peripheral nervous system neoplasm	7.7e-05	0.000411	CcSEcCtD
Buprenorphine—Headache—Alitretinoin—peripheral nervous system neoplasm	7.7e-05	0.00041	CcSEcCtD
Buprenorphine—Urticaria—Etoposide—peripheral nervous system neoplasm	7.62e-05	0.000406	CcSEcCtD
Buprenorphine—Rhinitis—Epirubicin—peripheral nervous system neoplasm	7.59e-05	0.000404	CcSEcCtD
Buprenorphine—Abdominal pain—Etoposide—peripheral nervous system neoplasm	7.58e-05	0.000404	CcSEcCtD
Buprenorphine—Body temperature increased—Etoposide—peripheral nervous system neoplasm	7.58e-05	0.000404	CcSEcCtD
Buprenorphine—Urinary tract infection—Doxorubicin—peripheral nervous system neoplasm	7.58e-05	0.000404	CcSEcCtD
Buprenorphine—Conjunctivitis—Doxorubicin—peripheral nervous system neoplasm	7.58e-05	0.000404	CcSEcCtD
Buprenorphine—Hypoaesthesia—Epirubicin—peripheral nervous system neoplasm	7.53e-05	0.000401	CcSEcCtD
Buprenorphine—Vomiting—Vincristine—peripheral nervous system neoplasm	7.53e-05	0.000401	CcSEcCtD
Buprenorphine—Asthenia—Cisplatin—peripheral nervous system neoplasm	7.51e-05	0.0004	CcSEcCtD
Buprenorphine—Pharyngitis—Epirubicin—peripheral nervous system neoplasm	7.51e-05	0.0004	CcSEcCtD
Buprenorphine—Sweating—Doxorubicin—peripheral nervous system neoplasm	7.48e-05	0.000399	CcSEcCtD
Buprenorphine—Urinary tract disorder—Epirubicin—peripheral nervous system neoplasm	7.47e-05	0.000398	CcSEcCtD
Buprenorphine—Rash—Vincristine—peripheral nervous system neoplasm	7.47e-05	0.000398	CcSEcCtD
Buprenorphine—Dermatitis—Vincristine—peripheral nervous system neoplasm	7.46e-05	0.000398	CcSEcCtD
Buprenorphine—Oedema peripheral—Epirubicin—peripheral nervous system neoplasm	7.45e-05	0.000397	CcSEcCtD
Buprenorphine—Connective tissue disorder—Epirubicin—peripheral nervous system neoplasm	7.44e-05	0.000396	CcSEcCtD
Buprenorphine—Urethral disorder—Epirubicin—peripheral nervous system neoplasm	7.42e-05	0.000395	CcSEcCtD
Buprenorphine—Headache—Vincristine—peripheral nervous system neoplasm	7.42e-05	0.000395	CcSEcCtD
Buprenorphine—Hepatobiliary disease—Doxorubicin—peripheral nervous system neoplasm	7.38e-05	0.000393	CcSEcCtD
Buprenorphine—Sinusitis—Doxorubicin—peripheral nervous system neoplasm	7.32e-05	0.00039	CcSEcCtD
Buprenorphine—Nausea—Alitretinoin—peripheral nervous system neoplasm	7.3e-05	0.000389	CcSEcCtD
Buprenorphine—Visual impairment—Epirubicin—peripheral nervous system neoplasm	7.29e-05	0.000389	CcSEcCtD
Buprenorphine—Diarrhoea—Cisplatin—peripheral nervous system neoplasm	7.16e-05	0.000382	CcSEcCtD
Buprenorphine—Bradycardia—Doxorubicin—peripheral nervous system neoplasm	7.13e-05	0.00038	CcSEcCtD
Buprenorphine—Eye disorder—Epirubicin—peripheral nervous system neoplasm	7.07e-05	0.000377	CcSEcCtD
Buprenorphine—Hypersensitivity—Etoposide—peripheral nervous system neoplasm	7.07e-05	0.000377	CcSEcCtD
Buprenorphine—Tinnitus—Epirubicin—peripheral nervous system neoplasm	7.06e-05	0.000376	CcSEcCtD
Buprenorphine—Nausea—Vincristine—peripheral nervous system neoplasm	7.03e-05	0.000375	CcSEcCtD
Buprenorphine—Flushing—Epirubicin—peripheral nervous system neoplasm	7.02e-05	0.000374	CcSEcCtD
Buprenorphine—Cardiac disorder—Epirubicin—peripheral nervous system neoplasm	7.02e-05	0.000374	CcSEcCtD
Buprenorphine—Rhinitis—Doxorubicin—peripheral nervous system neoplasm	7.02e-05	0.000374	CcSEcCtD
Buprenorphine—Hypoaesthesia—Doxorubicin—peripheral nervous system neoplasm	6.97e-05	0.000371	CcSEcCtD
Buprenorphine—Pharyngitis—Doxorubicin—peripheral nervous system neoplasm	6.95e-05	0.00037	CcSEcCtD
Buprenorphine—Urinary tract disorder—Doxorubicin—peripheral nervous system neoplasm	6.91e-05	0.000369	CcSEcCtD
Buprenorphine—Oedema peripheral—Doxorubicin—peripheral nervous system neoplasm	6.9e-05	0.000368	CcSEcCtD
Buprenorphine—Asthenia—Etoposide—peripheral nervous system neoplasm	6.88e-05	0.000367	CcSEcCtD
Buprenorphine—Connective tissue disorder—Doxorubicin—peripheral nervous system neoplasm	6.88e-05	0.000367	CcSEcCtD
Buprenorphine—Angiopathy—Epirubicin—peripheral nervous system neoplasm	6.87e-05	0.000366	CcSEcCtD
Buprenorphine—Urethral disorder—Doxorubicin—peripheral nervous system neoplasm	6.86e-05	0.000366	CcSEcCtD
Buprenorphine—Immune system disorder—Epirubicin—peripheral nervous system neoplasm	6.84e-05	0.000364	CcSEcCtD
Buprenorphine—Mediastinal disorder—Epirubicin—peripheral nervous system neoplasm	6.82e-05	0.000363	CcSEcCtD
Buprenorphine—Chills—Epirubicin—peripheral nervous system neoplasm	6.79e-05	0.000362	CcSEcCtD
Buprenorphine—Pruritus—Etoposide—peripheral nervous system neoplasm	6.79e-05	0.000362	CcSEcCtD
Buprenorphine—Visual impairment—Doxorubicin—peripheral nervous system neoplasm	6.75e-05	0.00036	CcSEcCtD
Buprenorphine—Vomiting—Cisplatin—peripheral nervous system neoplasm	6.66e-05	0.000355	CcSEcCtD
Buprenorphine—Mental disorder—Epirubicin—peripheral nervous system neoplasm	6.63e-05	0.000353	CcSEcCtD
Buprenorphine—Rash—Cisplatin—peripheral nervous system neoplasm	6.6e-05	0.000352	CcSEcCtD
Buprenorphine—Dermatitis—Cisplatin—peripheral nervous system neoplasm	6.59e-05	0.000351	CcSEcCtD
Buprenorphine—Malnutrition—Epirubicin—peripheral nervous system neoplasm	6.59e-05	0.000351	CcSEcCtD
Buprenorphine—Erythema—Epirubicin—peripheral nervous system neoplasm	6.59e-05	0.000351	CcSEcCtD
Buprenorphine—Diarrhoea—Etoposide—peripheral nervous system neoplasm	6.56e-05	0.00035	CcSEcCtD
Buprenorphine—Eye disorder—Doxorubicin—peripheral nervous system neoplasm	6.54e-05	0.000349	CcSEcCtD
Buprenorphine—Tinnitus—Doxorubicin—peripheral nervous system neoplasm	6.53e-05	0.000348	CcSEcCtD
Buprenorphine—Flushing—Doxorubicin—peripheral nervous system neoplasm	6.5e-05	0.000346	CcSEcCtD
Buprenorphine—Cardiac disorder—Doxorubicin—peripheral nervous system neoplasm	6.5e-05	0.000346	CcSEcCtD
Buprenorphine—Flatulence—Epirubicin—peripheral nervous system neoplasm	6.49e-05	0.000346	CcSEcCtD
Buprenorphine—Tension—Epirubicin—peripheral nervous system neoplasm	6.46e-05	0.000345	CcSEcCtD
Buprenorphine—Dysgeusia—Epirubicin—peripheral nervous system neoplasm	6.45e-05	0.000344	CcSEcCtD
Buprenorphine—Nervousness—Epirubicin—peripheral nervous system neoplasm	6.4e-05	0.000341	CcSEcCtD
Buprenorphine—Back pain—Epirubicin—peripheral nervous system neoplasm	6.37e-05	0.00034	CcSEcCtD
Buprenorphine—Angiopathy—Doxorubicin—peripheral nervous system neoplasm	6.35e-05	0.000339	CcSEcCtD
Buprenorphine—Dizziness—Etoposide—peripheral nervous system neoplasm	6.34e-05	0.000338	CcSEcCtD
Buprenorphine—Muscle spasms—Epirubicin—peripheral nervous system neoplasm	6.33e-05	0.000338	CcSEcCtD
Buprenorphine—Immune system disorder—Doxorubicin—peripheral nervous system neoplasm	6.32e-05	0.000337	CcSEcCtD
Buprenorphine—Mediastinal disorder—Doxorubicin—peripheral nervous system neoplasm	6.31e-05	0.000336	CcSEcCtD
Buprenorphine—Chills—Doxorubicin—peripheral nervous system neoplasm	6.28e-05	0.000335	CcSEcCtD
Buprenorphine—Nausea—Cisplatin—peripheral nervous system neoplasm	6.22e-05	0.000331	CcSEcCtD
Buprenorphine—Vision blurred—Epirubicin—peripheral nervous system neoplasm	6.21e-05	0.000331	CcSEcCtD
Buprenorphine—Mental disorder—Doxorubicin—peripheral nervous system neoplasm	6.13e-05	0.000327	CcSEcCtD
Buprenorphine—Ill-defined disorder—Epirubicin—peripheral nervous system neoplasm	6.11e-05	0.000326	CcSEcCtD
Buprenorphine—Vomiting—Etoposide—peripheral nervous system neoplasm	6.1e-05	0.000325	CcSEcCtD
Buprenorphine—Erythema—Doxorubicin—peripheral nervous system neoplasm	6.1e-05	0.000325	CcSEcCtD
Buprenorphine—Malnutrition—Doxorubicin—peripheral nervous system neoplasm	6.1e-05	0.000325	CcSEcCtD
Buprenorphine—Agitation—Epirubicin—peripheral nervous system neoplasm	6.05e-05	0.000323	CcSEcCtD
Buprenorphine—Rash—Etoposide—peripheral nervous system neoplasm	6.05e-05	0.000322	CcSEcCtD
Buprenorphine—Dermatitis—Etoposide—peripheral nervous system neoplasm	6.04e-05	0.000322	CcSEcCtD
Buprenorphine—Headache—Etoposide—peripheral nervous system neoplasm	6.01e-05	0.00032	CcSEcCtD
Buprenorphine—Flatulence—Doxorubicin—peripheral nervous system neoplasm	6.01e-05	0.00032	CcSEcCtD
Buprenorphine—Tension—Doxorubicin—peripheral nervous system neoplasm	5.98e-05	0.000319	CcSEcCtD
Buprenorphine—Dysgeusia—Doxorubicin—peripheral nervous system neoplasm	5.97e-05	0.000318	CcSEcCtD
Buprenorphine—Malaise—Epirubicin—peripheral nervous system neoplasm	5.94e-05	0.000317	CcSEcCtD
Buprenorphine—Nervousness—Doxorubicin—peripheral nervous system neoplasm	5.92e-05	0.000316	CcSEcCtD
Buprenorphine—Vertigo—Epirubicin—peripheral nervous system neoplasm	5.92e-05	0.000315	CcSEcCtD
Buprenorphine—Syncope—Epirubicin—peripheral nervous system neoplasm	5.91e-05	0.000315	CcSEcCtD
Buprenorphine—Back pain—Doxorubicin—peripheral nervous system neoplasm	5.9e-05	0.000314	CcSEcCtD
Buprenorphine—Muscle spasms—Doxorubicin—peripheral nervous system neoplasm	5.86e-05	0.000312	CcSEcCtD
Buprenorphine—Palpitations—Epirubicin—peripheral nervous system neoplasm	5.82e-05	0.00031	CcSEcCtD
Buprenorphine—Loss of consciousness—Epirubicin—peripheral nervous system neoplasm	5.79e-05	0.000309	CcSEcCtD
Buprenorphine—Cough—Epirubicin—peripheral nervous system neoplasm	5.75e-05	0.000306	CcSEcCtD
Buprenorphine—Vision blurred—Doxorubicin—peripheral nervous system neoplasm	5.74e-05	0.000306	CcSEcCtD
Buprenorphine—Convulsion—Epirubicin—peripheral nervous system neoplasm	5.71e-05	0.000304	CcSEcCtD
Buprenorphine—Nausea—Etoposide—peripheral nervous system neoplasm	5.7e-05	0.000304	CcSEcCtD
Buprenorphine—Hypertension—Epirubicin—peripheral nervous system neoplasm	5.69e-05	0.000303	CcSEcCtD
Buprenorphine—Ill-defined disorder—Doxorubicin—peripheral nervous system neoplasm	5.66e-05	0.000301	CcSEcCtD
Buprenorphine—Chest pain—Epirubicin—peripheral nervous system neoplasm	5.61e-05	0.000299	CcSEcCtD
Buprenorphine—Myalgia—Epirubicin—peripheral nervous system neoplasm	5.61e-05	0.000299	CcSEcCtD
Buprenorphine—Arthralgia—Epirubicin—peripheral nervous system neoplasm	5.61e-05	0.000299	CcSEcCtD
Buprenorphine—Agitation—Doxorubicin—peripheral nervous system neoplasm	5.6e-05	0.000299	CcSEcCtD
Buprenorphine—Anxiety—Epirubicin—peripheral nervous system neoplasm	5.59e-05	0.000298	CcSEcCtD
Buprenorphine—Unspecified disorder of skin and subcutaneous tissue—Epirubicin—peripheral nervous system neoplasm	5.57e-05	0.000297	CcSEcCtD
Buprenorphine—Discomfort—Epirubicin—peripheral nervous system neoplasm	5.54e-05	0.000295	CcSEcCtD
Buprenorphine—Malaise—Doxorubicin—peripheral nervous system neoplasm	5.5e-05	0.000293	CcSEcCtD
Buprenorphine—Dry mouth—Epirubicin—peripheral nervous system neoplasm	5.48e-05	0.000292	CcSEcCtD
Buprenorphine—Vertigo—Doxorubicin—peripheral nervous system neoplasm	5.48e-05	0.000292	CcSEcCtD
Buprenorphine—Syncope—Doxorubicin—peripheral nervous system neoplasm	5.47e-05	0.000291	CcSEcCtD
Buprenorphine—Confusional state—Epirubicin—peripheral nervous system neoplasm	5.42e-05	0.000289	CcSEcCtD
Buprenorphine—Palpitations—Doxorubicin—peripheral nervous system neoplasm	5.39e-05	0.000287	CcSEcCtD
Buprenorphine—Anaphylactic shock—Epirubicin—peripheral nervous system neoplasm	5.38e-05	0.000287	CcSEcCtD
Buprenorphine—Oedema—Epirubicin—peripheral nervous system neoplasm	5.38e-05	0.000287	CcSEcCtD
Buprenorphine—Loss of consciousness—Doxorubicin—peripheral nervous system neoplasm	5.36e-05	0.000286	CcSEcCtD
Buprenorphine—Infection—Epirubicin—peripheral nervous system neoplasm	5.34e-05	0.000285	CcSEcCtD
Buprenorphine—Cough—Doxorubicin—peripheral nervous system neoplasm	5.32e-05	0.000283	CcSEcCtD
Buprenorphine—Shock—Epirubicin—peripheral nervous system neoplasm	5.29e-05	0.000282	CcSEcCtD
Buprenorphine—Convulsion—Doxorubicin—peripheral nervous system neoplasm	5.28e-05	0.000281	CcSEcCtD
Buprenorphine—Nervous system disorder—Epirubicin—peripheral nervous system neoplasm	5.27e-05	0.000281	CcSEcCtD
Buprenorphine—Hypertension—Doxorubicin—peripheral nervous system neoplasm	5.26e-05	0.00028	CcSEcCtD
Buprenorphine—Tachycardia—Epirubicin—peripheral nervous system neoplasm	5.25e-05	0.00028	CcSEcCtD
Buprenorphine—Skin disorder—Epirubicin—peripheral nervous system neoplasm	5.22e-05	0.000278	CcSEcCtD
Buprenorphine—Hyperhidrosis—Epirubicin—peripheral nervous system neoplasm	5.2e-05	0.000277	CcSEcCtD
Buprenorphine—Arthralgia—Doxorubicin—peripheral nervous system neoplasm	5.19e-05	0.000277	CcSEcCtD
Buprenorphine—Myalgia—Doxorubicin—peripheral nervous system neoplasm	5.19e-05	0.000277	CcSEcCtD
Buprenorphine—Chest pain—Doxorubicin—peripheral nervous system neoplasm	5.19e-05	0.000277	CcSEcCtD
Buprenorphine—Anxiety—Doxorubicin—peripheral nervous system neoplasm	5.17e-05	0.000276	CcSEcCtD
Buprenorphine—Unspecified disorder of skin and subcutaneous tissue—Doxorubicin—peripheral nervous system neoplasm	5.15e-05	0.000275	CcSEcCtD
Buprenorphine—Discomfort—Doxorubicin—peripheral nervous system neoplasm	5.13e-05	0.000273	CcSEcCtD
Buprenorphine—Anorexia—Epirubicin—peripheral nervous system neoplasm	5.12e-05	0.000273	CcSEcCtD
Buprenorphine—Dry mouth—Doxorubicin—peripheral nervous system neoplasm	5.07e-05	0.00027	CcSEcCtD
Buprenorphine—Hypotension—Epirubicin—peripheral nervous system neoplasm	5.02e-05	0.000268	CcSEcCtD
Buprenorphine—Confusional state—Doxorubicin—peripheral nervous system neoplasm	5.02e-05	0.000267	CcSEcCtD
Buprenorphine—Anaphylactic shock—Doxorubicin—peripheral nervous system neoplasm	4.97e-05	0.000265	CcSEcCtD
Buprenorphine—Oedema—Doxorubicin—peripheral nervous system neoplasm	4.97e-05	0.000265	CcSEcCtD
Buprenorphine—Infection—Doxorubicin—peripheral nervous system neoplasm	4.94e-05	0.000263	CcSEcCtD
Buprenorphine—Musculoskeletal discomfort—Epirubicin—peripheral nervous system neoplasm	4.9e-05	0.000261	CcSEcCtD
Buprenorphine—Shock—Doxorubicin—peripheral nervous system neoplasm	4.89e-05	0.000261	CcSEcCtD
Buprenorphine—Nervous system disorder—Doxorubicin—peripheral nervous system neoplasm	4.88e-05	0.00026	CcSEcCtD
Buprenorphine—Insomnia—Epirubicin—peripheral nervous system neoplasm	4.86e-05	0.000259	CcSEcCtD
Buprenorphine—Tachycardia—Doxorubicin—peripheral nervous system neoplasm	4.85e-05	0.000259	CcSEcCtD
Buprenorphine—Skin disorder—Doxorubicin—peripheral nervous system neoplasm	4.83e-05	0.000258	CcSEcCtD
Buprenorphine—Paraesthesia—Epirubicin—peripheral nervous system neoplasm	4.83e-05	0.000257	CcSEcCtD
Buprenorphine—Hyperhidrosis—Doxorubicin—peripheral nervous system neoplasm	4.81e-05	0.000256	CcSEcCtD
Buprenorphine—Dyspnoea—Epirubicin—peripheral nervous system neoplasm	4.79e-05	0.000255	CcSEcCtD
Buprenorphine—Somnolence—Epirubicin—peripheral nervous system neoplasm	4.78e-05	0.000255	CcSEcCtD
Buprenorphine—Anorexia—Doxorubicin—peripheral nervous system neoplasm	4.74e-05	0.000253	CcSEcCtD
Buprenorphine—Dyspepsia—Epirubicin—peripheral nervous system neoplasm	4.73e-05	0.000252	CcSEcCtD
Buprenorphine—Decreased appetite—Epirubicin—peripheral nervous system neoplasm	4.67e-05	0.000249	CcSEcCtD
Buprenorphine—Hypotension—Doxorubicin—peripheral nervous system neoplasm	4.65e-05	0.000248	CcSEcCtD
Buprenorphine—Gastrointestinal disorder—Epirubicin—peripheral nervous system neoplasm	4.64e-05	0.000247	CcSEcCtD
Buprenorphine—Fatigue—Epirubicin—peripheral nervous system neoplasm	4.64e-05	0.000247	CcSEcCtD
Buprenorphine—Constipation—Epirubicin—peripheral nervous system neoplasm	4.6e-05	0.000245	CcSEcCtD
Buprenorphine—Pain—Epirubicin—peripheral nervous system neoplasm	4.6e-05	0.000245	CcSEcCtD
Buprenorphine—Musculoskeletal discomfort—Doxorubicin—peripheral nervous system neoplasm	4.53e-05	0.000242	CcSEcCtD
Buprenorphine—Insomnia—Doxorubicin—peripheral nervous system neoplasm	4.5e-05	0.00024	CcSEcCtD
Buprenorphine—Paraesthesia—Doxorubicin—peripheral nervous system neoplasm	4.47e-05	0.000238	CcSEcCtD
Buprenorphine—Dyspnoea—Doxorubicin—peripheral nervous system neoplasm	4.43e-05	0.000236	CcSEcCtD
Buprenorphine—Feeling abnormal—Epirubicin—peripheral nervous system neoplasm	4.43e-05	0.000236	CcSEcCtD
Buprenorphine—Somnolence—Doxorubicin—peripheral nervous system neoplasm	4.42e-05	0.000236	CcSEcCtD
Buprenorphine—Gastrointestinal pain—Epirubicin—peripheral nervous system neoplasm	4.4e-05	0.000234	CcSEcCtD
Buprenorphine—Dyspepsia—Doxorubicin—peripheral nervous system neoplasm	4.38e-05	0.000233	CcSEcCtD
Buprenorphine—Decreased appetite—Doxorubicin—peripheral nervous system neoplasm	4.32e-05	0.00023	CcSEcCtD
Buprenorphine—Gastrointestinal disorder—Doxorubicin—peripheral nervous system neoplasm	4.29e-05	0.000229	CcSEcCtD
Buprenorphine—Fatigue—Doxorubicin—peripheral nervous system neoplasm	4.29e-05	0.000229	CcSEcCtD
Buprenorphine—Urticaria—Epirubicin—peripheral nervous system neoplasm	4.27e-05	0.000228	CcSEcCtD
Buprenorphine—Constipation—Doxorubicin—peripheral nervous system neoplasm	4.25e-05	0.000227	CcSEcCtD
Buprenorphine—Pain—Doxorubicin—peripheral nervous system neoplasm	4.25e-05	0.000227	CcSEcCtD
Buprenorphine—Body temperature increased—Epirubicin—peripheral nervous system neoplasm	4.25e-05	0.000227	CcSEcCtD
Buprenorphine—Abdominal pain—Epirubicin—peripheral nervous system neoplasm	4.25e-05	0.000227	CcSEcCtD
Buprenorphine—Feeling abnormal—Doxorubicin—peripheral nervous system neoplasm	4.1e-05	0.000218	CcSEcCtD
Buprenorphine—Gastrointestinal pain—Doxorubicin—peripheral nervous system neoplasm	4.07e-05	0.000217	CcSEcCtD
Buprenorphine—Hypersensitivity—Epirubicin—peripheral nervous system neoplasm	3.96e-05	0.000211	CcSEcCtD
Buprenorphine—Urticaria—Doxorubicin—peripheral nervous system neoplasm	3.95e-05	0.000211	CcSEcCtD
Buprenorphine—Body temperature increased—Doxorubicin—peripheral nervous system neoplasm	3.93e-05	0.00021	CcSEcCtD
Buprenorphine—Abdominal pain—Doxorubicin—peripheral nervous system neoplasm	3.93e-05	0.00021	CcSEcCtD
Buprenorphine—Asthenia—Epirubicin—peripheral nervous system neoplasm	3.86e-05	0.000206	CcSEcCtD
Buprenorphine—Pruritus—Epirubicin—peripheral nervous system neoplasm	3.8e-05	0.000203	CcSEcCtD
Buprenorphine—Diarrhoea—Epirubicin—peripheral nervous system neoplasm	3.68e-05	0.000196	CcSEcCtD
Buprenorphine—Hypersensitivity—Doxorubicin—peripheral nervous system neoplasm	3.66e-05	0.000195	CcSEcCtD
Buprenorphine—Asthenia—Doxorubicin—peripheral nervous system neoplasm	3.57e-05	0.00019	CcSEcCtD
Buprenorphine—Dizziness—Epirubicin—peripheral nervous system neoplasm	3.56e-05	0.000189	CcSEcCtD
Buprenorphine—Pruritus—Doxorubicin—peripheral nervous system neoplasm	3.52e-05	0.000188	CcSEcCtD
Buprenorphine—Vomiting—Epirubicin—peripheral nervous system neoplasm	3.42e-05	0.000182	CcSEcCtD
Buprenorphine—Diarrhoea—Doxorubicin—peripheral nervous system neoplasm	3.4e-05	0.000181	CcSEcCtD
Buprenorphine—Rash—Epirubicin—peripheral nervous system neoplasm	3.39e-05	0.000181	CcSEcCtD
Buprenorphine—Dermatitis—Epirubicin—peripheral nervous system neoplasm	3.39e-05	0.000181	CcSEcCtD
Buprenorphine—Headache—Epirubicin—peripheral nervous system neoplasm	3.37e-05	0.00018	CcSEcCtD
Buprenorphine—Dizziness—Doxorubicin—peripheral nervous system neoplasm	3.29e-05	0.000175	CcSEcCtD
Buprenorphine—Nausea—Epirubicin—peripheral nervous system neoplasm	3.19e-05	0.00017	CcSEcCtD
Buprenorphine—Vomiting—Doxorubicin—peripheral nervous system neoplasm	3.16e-05	0.000169	CcSEcCtD
Buprenorphine—Rash—Doxorubicin—peripheral nervous system neoplasm	3.14e-05	0.000167	CcSEcCtD
Buprenorphine—Dermatitis—Doxorubicin—peripheral nervous system neoplasm	3.13e-05	0.000167	CcSEcCtD
Buprenorphine—Headache—Doxorubicin—peripheral nervous system neoplasm	3.12e-05	0.000166	CcSEcCtD
Buprenorphine—Nausea—Doxorubicin—peripheral nervous system neoplasm	2.95e-05	0.000157	CcSEcCtD
Buprenorphine—OPRM1—Signaling by GPCR—VIP—peripheral nervous system neoplasm	1.44e-05	0.00158	CbGpPWpGaD
Buprenorphine—OPRM1—TCR Signaling Pathway—AKT1—peripheral nervous system neoplasm	1.4e-05	0.00153	CbGpPWpGaD
Buprenorphine—OPRL1—Signaling Pathways—GNAS—peripheral nervous system neoplasm	1.4e-05	0.00153	CbGpPWpGaD
Buprenorphine—CYP1A2—Aryl Hydrocarbon Receptor—NRAS—peripheral nervous system neoplasm	1.39e-05	0.00152	CbGpPWpGaD
Buprenorphine—UGT1A9—Metabolism—GNS—peripheral nervous system neoplasm	1.38e-05	0.00151	CbGpPWpGaD
Buprenorphine—ABCB1—Allograft Rejection—CASP3—peripheral nervous system neoplasm	1.35e-05	0.00148	CbGpPWpGaD
Buprenorphine—OPRM1—Signaling by GPCR—PPP3R1—peripheral nervous system neoplasm	1.33e-05	0.00146	CbGpPWpGaD
Buprenorphine—OPRK1—Signaling Pathways—NTS—peripheral nervous system neoplasm	1.33e-05	0.00146	CbGpPWpGaD
Buprenorphine—ABCB1—Integrated Pancreatic Cancer Pathway—BDNF—peripheral nervous system neoplasm	1.33e-05	0.00146	CbGpPWpGaD
Buprenorphine—CYP2C19—Metabolism—PPIP5K2—peripheral nervous system neoplasm	1.33e-05	0.00145	CbGpPWpGaD
Buprenorphine—UGT1A9—Metabolism—NME1—peripheral nervous system neoplasm	1.32e-05	0.00144	CbGpPWpGaD
Buprenorphine—CYP1A2—Aryl Hydrocarbon Receptor—MYC—peripheral nervous system neoplasm	1.3e-05	0.00142	CbGpPWpGaD
Buprenorphine—ABCB1—Metabolism—PPIP5K2—peripheral nervous system neoplasm	1.29e-05	0.00142	CbGpPWpGaD
Buprenorphine—OPRK1—Signaling Pathways—CD55—peripheral nervous system neoplasm	1.28e-05	0.0014	CbGpPWpGaD
Buprenorphine—OPRD1—GPCR downstream signaling—KNG1—peripheral nervous system neoplasm	1.27e-05	0.00139	CbGpPWpGaD
Buprenorphine—UGT1A9—Metabolism—COX2—peripheral nervous system neoplasm	1.27e-05	0.00139	CbGpPWpGaD
Buprenorphine—ABCB1—Transmembrane transport of small molecules—COX2—peripheral nervous system neoplasm	1.24e-05	0.00136	CbGpPWpGaD
Buprenorphine—CYP2D6—Metabolism—PPIP5K2—peripheral nervous system neoplasm	1.22e-05	0.00133	CbGpPWpGaD
Buprenorphine—ABCG2—Transmembrane transport of small molecules—SLC2A1—peripheral nervous system neoplasm	1.22e-05	0.00133	CbGpPWpGaD
Buprenorphine—CYP2C9—Metabolism—PPIP5K2—peripheral nervous system neoplasm	1.21e-05	0.00132	CbGpPWpGaD
Buprenorphine—ABCG2—Metabolism—GNS—peripheral nervous system neoplasm	1.17e-05	0.00128	CbGpPWpGaD
Buprenorphine—CYP3A7—Metabolism—GNS—peripheral nervous system neoplasm	1.16e-05	0.00127	CbGpPWpGaD
Buprenorphine—CYP3A5—Metabolism—HSD17B12—peripheral nervous system neoplasm	1.16e-05	0.00127	CbGpPWpGaD
Buprenorphine—OPRD1—Signaling by GPCR—KNG1—peripheral nervous system neoplasm	1.16e-05	0.00126	CbGpPWpGaD
Buprenorphine—OPRD1—Signaling Pathways—VIP—peripheral nervous system neoplasm	1.15e-05	0.00126	CbGpPWpGaD
Buprenorphine—OPRM1—Signaling Pathways—NTS—peripheral nervous system neoplasm	1.13e-05	0.00123	CbGpPWpGaD
Buprenorphine—ABCG2—Metabolism—NME1—peripheral nervous system neoplasm	1.12e-05	0.00123	CbGpPWpGaD
Buprenorphine—OPRK1—GPCR downstream signaling—KNG1—peripheral nervous system neoplasm	1.12e-05	0.00122	CbGpPWpGaD
Buprenorphine—OPRD1—GPCR downstream signaling—GNAS—peripheral nervous system neoplasm	1.11e-05	0.00122	CbGpPWpGaD
Buprenorphine—CYP3A7—Metabolism—NME1—peripheral nervous system neoplasm	1.11e-05	0.00121	CbGpPWpGaD
Buprenorphine—OPRM1—Signaling Pathways—CD55—peripheral nervous system neoplasm	1.08e-05	0.00118	CbGpPWpGaD
Buprenorphine—ABCG2—Metabolism—COX2—peripheral nervous system neoplasm	1.08e-05	0.00118	CbGpPWpGaD
Buprenorphine—CYP3A7—Metabolism—COX2—peripheral nervous system neoplasm	1.07e-05	0.00117	CbGpPWpGaD
Buprenorphine—OPRD1—Signaling Pathways—PPP3R1—peripheral nervous system neoplasm	1.06e-05	0.00116	CbGpPWpGaD
Buprenorphine—CYP2A6—Metabolism—GNS—peripheral nervous system neoplasm	1.06e-05	0.00116	CbGpPWpGaD
Buprenorphine—CYP2C18—Metabolism—ENO2—peripheral nervous system neoplasm	1.06e-05	0.00115	CbGpPWpGaD
Buprenorphine—CYP1A2—Metabolism—PPIP5K2—peripheral nervous system neoplasm	1.03e-05	0.00113	CbGpPWpGaD
Buprenorphine—CYP2A6—Metabolism—NME1—peripheral nervous system neoplasm	1.02e-05	0.00111	CbGpPWpGaD
Buprenorphine—CYP1A2—Aryl Hydrocarbon Receptor—HRAS—peripheral nervous system neoplasm	1.02e-05	0.00111	CbGpPWpGaD
Buprenorphine—OPRK1—Signaling by GPCR—KNG1—peripheral nervous system neoplasm	1.01e-05	0.00111	CbGpPWpGaD
Buprenorphine—OPRD1—Signaling by GPCR—GNAS—peripheral nervous system neoplasm	1.01e-05	0.00111	CbGpPWpGaD
Buprenorphine—OPRK1—Signaling Pathways—VIP—peripheral nervous system neoplasm	1.01e-05	0.0011	CbGpPWpGaD
Buprenorphine—CYP2C8—Metabolism—HSD17B12—peripheral nervous system neoplasm	1e-05	0.0011	CbGpPWpGaD
Buprenorphine—OPRL1—Signaling by GPCR—NRAS—peripheral nervous system neoplasm	9.89e-06	0.00108	CbGpPWpGaD
Buprenorphine—ABCG2—Transmembrane transport of small molecules—GNAS—peripheral nervous system neoplasm	9.8e-06	0.00107	CbGpPWpGaD
Buprenorphine—CYP2A6—Metabolism—COX2—peripheral nervous system neoplasm	9.79e-06	0.00107	CbGpPWpGaD
Buprenorphine—OPRK1—GPCR downstream signaling—GNAS—peripheral nervous system neoplasm	9.76e-06	0.00107	CbGpPWpGaD
Buprenorphine—OPRL1—Signaling Pathways—PTPN11—peripheral nervous system neoplasm	9.72e-06	0.00106	CbGpPWpGaD
Buprenorphine—ABCG2—Transmembrane transport of small molecules—ABCB1—peripheral nervous system neoplasm	9.62e-06	0.00105	CbGpPWpGaD
Buprenorphine—OPRM1—GPCR downstream signaling—KNG1—peripheral nervous system neoplasm	9.43e-06	0.00103	CbGpPWpGaD
Buprenorphine—OPRK1—Signaling Pathways—PPP3R1—peripheral nervous system neoplasm	9.32e-06	0.00102	CbGpPWpGaD
Buprenorphine—CYP2C19—Metabolism—HSD17B12—peripheral nervous system neoplasm	8.95e-06	0.000979	CbGpPWpGaD
Buprenorphine—CYP2C18—Metabolism—BCHE—peripheral nervous system neoplasm	8.92e-06	0.000976	CbGpPWpGaD
Buprenorphine—OPRK1—Signaling by GPCR—GNAS—peripheral nervous system neoplasm	8.86e-06	0.000969	CbGpPWpGaD
Buprenorphine—ABCB1—Metabolism—HSD17B12—peripheral nervous system neoplasm	8.74e-06	0.000956	CbGpPWpGaD
Buprenorphine—OPRM1—Signaling by GPCR—KNG1—peripheral nervous system neoplasm	8.56e-06	0.000937	CbGpPWpGaD
Buprenorphine—OPRM1—Signaling Pathways—VIP—peripheral nervous system neoplasm	8.53e-06	0.000934	CbGpPWpGaD
Buprenorphine—CYP2C18—Metabolism—SLC2A1—peripheral nervous system neoplasm	8.51e-06	0.000931	CbGpPWpGaD
Buprenorphine—ABCB1—HIF-1-alpha transcription factor network—AKT1—peripheral nervous system neoplasm	8.43e-06	0.000922	CbGpPWpGaD
Buprenorphine—CYP2C18—Metabolism—TH—peripheral nervous system neoplasm	8.38e-06	0.000917	CbGpPWpGaD
Buprenorphine—CYP3A5—Metabolism—GNS—peripheral nervous system neoplasm	8.37e-06	0.000916	CbGpPWpGaD
Buprenorphine—UGT1A9—Metabolism—ENO2—peripheral nervous system neoplasm	8.34e-06	0.000913	CbGpPWpGaD
Buprenorphine—CYP2C8—Metabolism of lipids and lipoproteins—BCHE—peripheral nervous system neoplasm	8.33e-06	0.000912	CbGpPWpGaD
Buprenorphine—OPRM1—GPCR downstream signaling—GNAS—peripheral nervous system neoplasm	8.25e-06	0.000902	CbGpPWpGaD
Buprenorphine—CYP2D6—Metabolism—HSD17B12—peripheral nervous system neoplasm	8.23e-06	0.000901	CbGpPWpGaD
Buprenorphine—CYP2C9—Metabolism—HSD17B12—peripheral nervous system neoplasm	8.16e-06	0.000893	CbGpPWpGaD
Buprenorphine—CYP3A5—Metabolism—NME1—peripheral nervous system neoplasm	8.02e-06	0.000878	CbGpPWpGaD
Buprenorphine—OPRD1—Signaling Pathways—NTRK2—peripheral nervous system neoplasm	7.98e-06	0.000873	CbGpPWpGaD
Buprenorphine—CYP3A4—Metabolism—PPIP5K2—peripheral nervous system neoplasm	7.97e-06	0.000872	CbGpPWpGaD
Buprenorphine—OPRM1—Signaling Pathways—PPP3R1—peripheral nervous system neoplasm	7.87e-06	0.000862	CbGpPWpGaD
Buprenorphine—CYP3A5—Metabolism—COX2—peripheral nervous system neoplasm	7.72e-06	0.000845	CbGpPWpGaD
Buprenorphine—OPRL1—Signaling Pathways—ERBB2—peripheral nervous system neoplasm	7.68e-06	0.00084	CbGpPWpGaD
Buprenorphine—OPRM1—Signaling by GPCR—GNAS—peripheral nervous system neoplasm	7.49e-06	0.000819	CbGpPWpGaD
Buprenorphine—CYP2C19—Metabolism of lipids and lipoproteins—BCHE—peripheral nervous system neoplasm	7.44e-06	0.000814	CbGpPWpGaD
Buprenorphine—ABCB1—Integrated Pancreatic Cancer Pathway—ERBB2—peripheral nervous system neoplasm	7.33e-06	0.000802	CbGpPWpGaD
Buprenorphine—CYP2C8—Metabolism—GNS—peripheral nervous system neoplasm	7.25e-06	0.000793	CbGpPWpGaD
Buprenorphine—OPRL1—Signaling by GPCR—HRAS—peripheral nervous system neoplasm	7.24e-06	0.000792	CbGpPWpGaD
Buprenorphine—ABCG2—Metabolism—ENO2—peripheral nervous system neoplasm	7.08e-06	0.000774	CbGpPWpGaD
Buprenorphine—UGT1A9—Metabolism—BCHE—peripheral nervous system neoplasm	7.05e-06	0.000771	CbGpPWpGaD
Buprenorphine—OPRL1—GPCR downstream signaling—AKT1—peripheral nervous system neoplasm	7.04e-06	0.00077	CbGpPWpGaD
Buprenorphine—OPRD1—Signaling by GPCR—PTPN11—peripheral nervous system neoplasm	7.02e-06	0.000768	CbGpPWpGaD
Buprenorphine—CYP3A7—Metabolism—ENO2—peripheral nervous system neoplasm	7.02e-06	0.000768	CbGpPWpGaD
Buprenorphine—OPRK1—Signaling Pathways—NTRK2—peripheral nervous system neoplasm	7e-06	0.000766	CbGpPWpGaD
Buprenorphine—CYP1A2—Metabolism—HSD17B12—peripheral nervous system neoplasm	6.97e-06	0.000763	CbGpPWpGaD
Buprenorphine—OPRL1—Signaling Pathways—CASP3—peripheral nervous system neoplasm	6.97e-06	0.000763	CbGpPWpGaD
Buprenorphine—CYP2C8—Metabolism—NME1—peripheral nervous system neoplasm	6.95e-06	0.000761	CbGpPWpGaD
Buprenorphine—CYP2C18—Metabolism—GNAS—peripheral nervous system neoplasm	6.84e-06	0.000749	CbGpPWpGaD
Buprenorphine—OPRD1—Signaling Pathways—KNG1—peripheral nervous system neoplasm	6.83e-06	0.000747	CbGpPWpGaD
Buprenorphine—CYP2C9—Metabolism of lipids and lipoproteins—BCHE—peripheral nervous system neoplasm	6.78e-06	0.000742	CbGpPWpGaD
Buprenorphine—UGT1A9—Metabolism—SLC2A1—peripheral nervous system neoplasm	6.72e-06	0.000736	CbGpPWpGaD
Buprenorphine—CYP2C18—Metabolism—ABCB1—peripheral nervous system neoplasm	6.72e-06	0.000735	CbGpPWpGaD
Buprenorphine—CYP2C8—Metabolism—COX2—peripheral nervous system neoplasm	6.69e-06	0.000732	CbGpPWpGaD
Buprenorphine—ABCB1—Integrated Pancreatic Cancer Pathway—CASP3—peripheral nervous system neoplasm	6.65e-06	0.000728	CbGpPWpGaD
Buprenorphine—UGT1A9—Metabolism—TH—peripheral nervous system neoplasm	6.63e-06	0.000725	CbGpPWpGaD
Buprenorphine—ABCB1—Transmembrane transport of small molecules—SLC2A1—peripheral nervous system neoplasm	6.59e-06	0.000721	CbGpPWpGaD
Buprenorphine—OPRD1—Signaling Pathways—NTRK1—peripheral nervous system neoplasm	6.51e-06	0.000712	CbGpPWpGaD
Buprenorphine—CYP2C19—Metabolism—GNS—peripheral nervous system neoplasm	6.47e-06	0.000708	CbGpPWpGaD
Buprenorphine—CYP2A6—Metabolism—ENO2—peripheral nervous system neoplasm	6.43e-06	0.000704	CbGpPWpGaD
Buprenorphine—OPRL1—Signaling by GPCR—AKT1—peripheral nervous system neoplasm	6.39e-06	0.000699	CbGpPWpGaD
Buprenorphine—ABCB1—Metabolism—GNS—peripheral nervous system neoplasm	6.32e-06	0.000691	CbGpPWpGaD
Buprenorphine—CYP2C19—Metabolism—NME1—peripheral nervous system neoplasm	6.2e-06	0.000679	CbGpPWpGaD
Buprenorphine—OPRK1—Signaling by GPCR—PTPN11—peripheral nervous system neoplasm	6.16e-06	0.000674	CbGpPWpGaD
Buprenorphine—ABCB1—Metabolism—NME1—peripheral nervous system neoplasm	6.06e-06	0.000663	CbGpPWpGaD
Buprenorphine—OPRK1—Signaling Pathways—KNG1—peripheral nervous system neoplasm	5.99e-06	0.000655	CbGpPWpGaD
Buprenorphine—ABCG2—Metabolism—BCHE—peripheral nervous system neoplasm	5.98e-06	0.000654	CbGpPWpGaD
Buprenorphine—CYP2C19—Metabolism—COX2—peripheral nervous system neoplasm	5.97e-06	0.000653	CbGpPWpGaD
Buprenorphine—OPRD1—Signaling Pathways—GNAS—peripheral nervous system neoplasm	5.97e-06	0.000653	CbGpPWpGaD
Buprenorphine—CYP2D6—Metabolism—GNS—peripheral nervous system neoplasm	5.95e-06	0.000651	CbGpPWpGaD
Buprenorphine—CYP3A7—Metabolism—BCHE—peripheral nervous system neoplasm	5.93e-06	0.000649	CbGpPWpGaD
Buprenorphine—OPRM1—Signaling Pathways—NTRK2—peripheral nervous system neoplasm	5.91e-06	0.000647	CbGpPWpGaD
Buprenorphine—CYP2C9—Metabolism—GNS—peripheral nervous system neoplasm	5.9e-06	0.000646	CbGpPWpGaD
Buprenorphine—OPRL1—Signaling Pathways—NRAS—peripheral nervous system neoplasm	5.84e-06	0.000639	CbGpPWpGaD
Buprenorphine—ABCB1—Metabolism—COX2—peripheral nervous system neoplasm	5.83e-06	0.000638	CbGpPWpGaD
Buprenorphine—CYP1A2—Metabolism of lipids and lipoproteins—BCHE—peripheral nervous system neoplasm	5.8e-06	0.000634	CbGpPWpGaD
Buprenorphine—CYP2D6—Metabolism—NME1—peripheral nervous system neoplasm	5.71e-06	0.000624	CbGpPWpGaD
Buprenorphine—ABCG2—Metabolism—SLC2A1—peripheral nervous system neoplasm	5.71e-06	0.000624	CbGpPWpGaD
Buprenorphine—OPRK1—Signaling Pathways—NTRK1—peripheral nervous system neoplasm	5.7e-06	0.000624	CbGpPWpGaD
Buprenorphine—CYP2C9—Metabolism—NME1—peripheral nervous system neoplasm	5.66e-06	0.000619	CbGpPWpGaD
Buprenorphine—CYP3A7—Metabolism—SLC2A1—peripheral nervous system neoplasm	5.65e-06	0.000619	CbGpPWpGaD
Buprenorphine—ABCG2—Metabolism—TH—peripheral nervous system neoplasm	5.62e-06	0.000615	CbGpPWpGaD
Buprenorphine—CYP3A7—Metabolism—TH—peripheral nervous system neoplasm	5.57e-06	0.00061	CbGpPWpGaD
Buprenorphine—CYP2D6—Metabolism—COX2—peripheral nervous system neoplasm	5.49e-06	0.000601	CbGpPWpGaD
Buprenorphine—CYP2C9—Metabolism—COX2—peripheral nervous system neoplasm	5.45e-06	0.000596	CbGpPWpGaD
Buprenorphine—OPRL1—Signaling Pathways—MYC—peripheral nervous system neoplasm	5.44e-06	0.000595	CbGpPWpGaD
Buprenorphine—CYP2A6—Metabolism—BCHE—peripheral nervous system neoplasm	5.43e-06	0.000594	CbGpPWpGaD
Buprenorphine—UGT1A9—Metabolism—GNAS—peripheral nervous system neoplasm	5.41e-06	0.000592	CbGpPWpGaD
Buprenorphine—CYP3A4—Metabolism—HSD17B12—peripheral nervous system neoplasm	5.38e-06	0.000589	CbGpPWpGaD
Buprenorphine—UGT1A9—Metabolism—ABCB1—peripheral nervous system neoplasm	5.31e-06	0.000581	CbGpPWpGaD
Buprenorphine—ABCB1—Transmembrane transport of small molecules—GNAS—peripheral nervous system neoplasm	5.3e-06	0.00058	CbGpPWpGaD
Buprenorphine—OPRK1—Signaling Pathways—GNAS—peripheral nervous system neoplasm	5.23e-06	0.000573	CbGpPWpGaD
Buprenorphine—OPRM1—Signaling by GPCR—PTPN11—peripheral nervous system neoplasm	5.2e-06	0.000569	CbGpPWpGaD
Buprenorphine—ABCB1—Integrated Pancreatic Cancer Pathway—MYC—peripheral nervous system neoplasm	5.19e-06	0.000568	CbGpPWpGaD
Buprenorphine—CYP2A6—Metabolism—SLC2A1—peripheral nervous system neoplasm	5.18e-06	0.000567	CbGpPWpGaD
Buprenorphine—CYP2A6—Metabolism—TH—peripheral nervous system neoplasm	5.11e-06	0.000559	CbGpPWpGaD
Buprenorphine—CYP3A5—Metabolism—ENO2—peripheral nervous system neoplasm	5.07e-06	0.000555	CbGpPWpGaD
Buprenorphine—OPRM1—Signaling Pathways—KNG1—peripheral nervous system neoplasm	5.06e-06	0.000553	CbGpPWpGaD
Buprenorphine—CYP1A2—Metabolism—GNS—peripheral nervous system neoplasm	5.04e-06	0.000552	CbGpPWpGaD
Buprenorphine—CYP1A2—Metabolism—NME1—peripheral nervous system neoplasm	4.83e-06	0.000529	CbGpPWpGaD
Buprenorphine—OPRM1—Signaling Pathways—NTRK1—peripheral nervous system neoplasm	4.82e-06	0.000527	CbGpPWpGaD
Buprenorphine—CYP1A2—Metabolism—COX2—peripheral nervous system neoplasm	4.65e-06	0.000509	CbGpPWpGaD
Buprenorphine—ABCG2—Metabolism—GNAS—peripheral nervous system neoplasm	4.59e-06	0.000502	CbGpPWpGaD
Buprenorphine—CYP3A7—Metabolism—GNAS—peripheral nervous system neoplasm	4.55e-06	0.000498	CbGpPWpGaD
Buprenorphine—ABCG2—Metabolism—ABCB1—peripheral nervous system neoplasm	4.5e-06	0.000493	CbGpPWpGaD
Buprenorphine—OPRL1—Signaling Pathways—TP53—peripheral nervous system neoplasm	4.47e-06	0.000489	CbGpPWpGaD
Buprenorphine—CYP3A7—Metabolism—ABCB1—peripheral nervous system neoplasm	4.46e-06	0.000488	CbGpPWpGaD
Buprenorphine—OPRM1—Signaling Pathways—GNAS—peripheral nervous system neoplasm	4.42e-06	0.000484	CbGpPWpGaD
Buprenorphine—CYP2C8—Metabolism—ENO2—peripheral nervous system neoplasm	4.39e-06	0.000481	CbGpPWpGaD
Buprenorphine—CYP3A5—Metabolism—BCHE—peripheral nervous system neoplasm	4.28e-06	0.000469	CbGpPWpGaD
Buprenorphine—OPRL1—Signaling Pathways—HRAS—peripheral nervous system neoplasm	4.27e-06	0.000468	CbGpPWpGaD
Buprenorphine—ABCB1—Integrated Pancreatic Cancer Pathway—TP53—peripheral nervous system neoplasm	4.27e-06	0.000467	CbGpPWpGaD
Buprenorphine—OPRD1—Signaling by GPCR—NRAS—peripheral nervous system neoplasm	4.22e-06	0.000462	CbGpPWpGaD
Buprenorphine—CYP2A6—Metabolism—GNAS—peripheral nervous system neoplasm	4.17e-06	0.000456	CbGpPWpGaD
Buprenorphine—OPRD1—Signaling Pathways—PTPN11—peripheral nervous system neoplasm	4.15e-06	0.000454	CbGpPWpGaD
Buprenorphine—CYP2A6—Metabolism—ABCB1—peripheral nervous system neoplasm	4.09e-06	0.000448	CbGpPWpGaD
Buprenorphine—CYP3A5—Metabolism—SLC2A1—peripheral nervous system neoplasm	4.09e-06	0.000447	CbGpPWpGaD
Buprenorphine—CYP3A5—Metabolism—TH—peripheral nervous system neoplasm	4.03e-06	0.000441	CbGpPWpGaD
Buprenorphine—CYP2C19—Metabolism—ENO2—peripheral nervous system neoplasm	3.92e-06	0.000429	CbGpPWpGaD
Buprenorphine—CYP3A4—Metabolism—GNS—peripheral nervous system neoplasm	3.89e-06	0.000426	CbGpPWpGaD
Buprenorphine—ABCB1—Metabolism—ENO2—peripheral nervous system neoplasm	3.83e-06	0.000419	CbGpPWpGaD
Buprenorphine—OPRL1—Signaling Pathways—AKT1—peripheral nervous system neoplasm	3.77e-06	0.000413	CbGpPWpGaD
Buprenorphine—CYP3A4—Metabolism—NME1—peripheral nervous system neoplasm	3.73e-06	0.000408	CbGpPWpGaD
Buprenorphine—CYP2C8—Metabolism—BCHE—peripheral nervous system neoplasm	3.71e-06	0.000406	CbGpPWpGaD
Buprenorphine—OPRK1—Signaling by GPCR—NRAS—peripheral nervous system neoplasm	3.7e-06	0.000405	CbGpPWpGaD
Buprenorphine—OPRK1—Signaling Pathways—PTPN11—peripheral nervous system neoplasm	3.64e-06	0.000398	CbGpPWpGaD
Buprenorphine—CYP2D6—Metabolism—ENO2—peripheral nervous system neoplasm	3.61e-06	0.000395	CbGpPWpGaD
Buprenorphine—ABCB1—Integrated Pancreatic Cancer Pathway—AKT1—peripheral nervous system neoplasm	3.6e-06	0.000394	CbGpPWpGaD
Buprenorphine—CYP3A4—Metabolism—COX2—peripheral nervous system neoplasm	3.59e-06	0.000393	CbGpPWpGaD
Buprenorphine—CYP2C9—Metabolism—ENO2—peripheral nervous system neoplasm	3.57e-06	0.000391	CbGpPWpGaD
Buprenorphine—CYP2C8—Metabolism—SLC2A1—peripheral nervous system neoplasm	3.54e-06	0.000387	CbGpPWpGaD
Buprenorphine—CYP2C8—Metabolism—TH—peripheral nervous system neoplasm	3.49e-06	0.000382	CbGpPWpGaD
Buprenorphine—CYP2C19—Metabolism—BCHE—peripheral nervous system neoplasm	3.31e-06	0.000362	CbGpPWpGaD
Buprenorphine—CYP3A5—Metabolism—GNAS—peripheral nervous system neoplasm	3.29e-06	0.00036	CbGpPWpGaD
Buprenorphine—OPRD1—Signaling Pathways—ERBB2—peripheral nervous system neoplasm	3.28e-06	0.000359	CbGpPWpGaD
Buprenorphine—ABCB1—Metabolism—BCHE—peripheral nervous system neoplasm	3.23e-06	0.000354	CbGpPWpGaD
Buprenorphine—CYP3A5—Metabolism—ABCB1—peripheral nervous system neoplasm	3.23e-06	0.000353	CbGpPWpGaD
Buprenorphine—CYP2C19—Metabolism—SLC2A1—peripheral nervous system neoplasm	3.16e-06	0.000346	CbGpPWpGaD
Buprenorphine—OPRM1—Signaling by GPCR—NRAS—peripheral nervous system neoplasm	3.13e-06	0.000342	CbGpPWpGaD
Buprenorphine—CYP2C19—Metabolism—TH—peripheral nervous system neoplasm	3.11e-06	0.000341	CbGpPWpGaD
Buprenorphine—OPRD1—Signaling by GPCR—HRAS—peripheral nervous system neoplasm	3.09e-06	0.000338	CbGpPWpGaD
Buprenorphine—ABCB1—Metabolism—SLC2A1—peripheral nervous system neoplasm	3.08e-06	0.000337	CbGpPWpGaD
Buprenorphine—OPRM1—Signaling Pathways—PTPN11—peripheral nervous system neoplasm	3.07e-06	0.000336	CbGpPWpGaD
Buprenorphine—CYP1A2—Metabolism—ENO2—peripheral nervous system neoplasm	3.05e-06	0.000334	CbGpPWpGaD
Buprenorphine—CYP2D6—Metabolism—BCHE—peripheral nervous system neoplasm	3.05e-06	0.000333	CbGpPWpGaD
Buprenorphine—ABCB1—Metabolism—TH—peripheral nervous system neoplasm	3.04e-06	0.000333	CbGpPWpGaD
Buprenorphine—CYP2C9—Metabolism—BCHE—peripheral nervous system neoplasm	3.02e-06	0.00033	CbGpPWpGaD
Buprenorphine—OPRD1—GPCR downstream signaling—AKT1—peripheral nervous system neoplasm	3e-06	0.000329	CbGpPWpGaD
Buprenorphine—OPRD1—Signaling Pathways—CASP3—peripheral nervous system neoplasm	2.98e-06	0.000326	CbGpPWpGaD
Buprenorphine—CYP2D6—Metabolism—SLC2A1—peripheral nervous system neoplasm	2.91e-06	0.000318	CbGpPWpGaD
Buprenorphine—CYP2C9—Metabolism—SLC2A1—peripheral nervous system neoplasm	2.88e-06	0.000315	CbGpPWpGaD
Buprenorphine—OPRK1—Signaling Pathways—ERBB2—peripheral nervous system neoplasm	2.87e-06	0.000315	CbGpPWpGaD
Buprenorphine—CYP2D6—Metabolism—TH—peripheral nervous system neoplasm	2.86e-06	0.000313	CbGpPWpGaD
Buprenorphine—CYP2C8—Metabolism—GNAS—peripheral nervous system neoplasm	2.85e-06	0.000312	CbGpPWpGaD
Buprenorphine—CYP2C9—Metabolism—TH—peripheral nervous system neoplasm	2.84e-06	0.000311	CbGpPWpGaD
Buprenorphine—CYP2C8—Metabolism—ABCB1—peripheral nervous system neoplasm	2.8e-06	0.000306	CbGpPWpGaD
Buprenorphine—OPRD1—Signaling by GPCR—AKT1—peripheral nervous system neoplasm	2.73e-06	0.000298	CbGpPWpGaD
Buprenorphine—OPRK1—Signaling by GPCR—HRAS—peripheral nervous system neoplasm	2.71e-06	0.000296	CbGpPWpGaD
Buprenorphine—OPRK1—GPCR downstream signaling—AKT1—peripheral nervous system neoplasm	2.63e-06	0.000288	CbGpPWpGaD
Buprenorphine—OPRK1—Signaling Pathways—CASP3—peripheral nervous system neoplasm	2.61e-06	0.000285	CbGpPWpGaD
Buprenorphine—CYP1A2—Metabolism—BCHE—peripheral nervous system neoplasm	2.58e-06	0.000282	CbGpPWpGaD
Buprenorphine—CYP2C19—Metabolism—GNAS—peripheral nervous system neoplasm	2.54e-06	0.000278	CbGpPWpGaD
Buprenorphine—CYP2C19—Metabolism—ABCB1—peripheral nervous system neoplasm	2.49e-06	0.000273	CbGpPWpGaD
Buprenorphine—OPRD1—Signaling Pathways—NRAS—peripheral nervous system neoplasm	2.49e-06	0.000273	CbGpPWpGaD
Buprenorphine—ABCB1—Metabolism—GNAS—peripheral nervous system neoplasm	2.48e-06	0.000272	CbGpPWpGaD
Buprenorphine—CYP1A2—Metabolism—SLC2A1—peripheral nervous system neoplasm	2.46e-06	0.000269	CbGpPWpGaD
Buprenorphine—OPRM1—Signaling Pathways—ERBB2—peripheral nervous system neoplasm	2.43e-06	0.000266	CbGpPWpGaD
Buprenorphine—CYP1A2—Metabolism—TH—peripheral nervous system neoplasm	2.43e-06	0.000266	CbGpPWpGaD
Buprenorphine—OPRK1—Signaling by GPCR—AKT1—peripheral nervous system neoplasm	2.39e-06	0.000262	CbGpPWpGaD
Buprenorphine—CYP3A4—Metabolism—ENO2—peripheral nervous system neoplasm	2.36e-06	0.000258	CbGpPWpGaD
Buprenorphine—CYP2D6—Metabolism—GNAS—peripheral nervous system neoplasm	2.34e-06	0.000256	CbGpPWpGaD
Buprenorphine—OPRD1—Signaling Pathways—MYC—peripheral nervous system neoplasm	2.32e-06	0.000254	CbGpPWpGaD
Buprenorphine—CYP2C9—Metabolism—GNAS—peripheral nervous system neoplasm	2.32e-06	0.000254	CbGpPWpGaD
Buprenorphine—CYP2D6—Metabolism—ABCB1—peripheral nervous system neoplasm	2.29e-06	0.000251	CbGpPWpGaD
Buprenorphine—OPRM1—Signaling by GPCR—HRAS—peripheral nervous system neoplasm	2.29e-06	0.00025	CbGpPWpGaD
Buprenorphine—CYP2C9—Metabolism—ABCB1—peripheral nervous system neoplasm	2.27e-06	0.000249	CbGpPWpGaD
Buprenorphine—OPRM1—GPCR downstream signaling—AKT1—peripheral nervous system neoplasm	2.23e-06	0.000244	CbGpPWpGaD
Buprenorphine—OPRM1—Signaling Pathways—CASP3—peripheral nervous system neoplasm	2.21e-06	0.000241	CbGpPWpGaD
Buprenorphine—OPRK1—Signaling Pathways—NRAS—peripheral nervous system neoplasm	2.19e-06	0.000239	CbGpPWpGaD
Buprenorphine—OPRK1—Signaling Pathways—MYC—peripheral nervous system neoplasm	2.04e-06	0.000223	CbGpPWpGaD
Buprenorphine—OPRM1—Signaling by GPCR—AKT1—peripheral nervous system neoplasm	2.02e-06	0.000221	CbGpPWpGaD
Buprenorphine—CYP3A4—Metabolism—BCHE—peripheral nervous system neoplasm	1.99e-06	0.000218	CbGpPWpGaD
Buprenorphine—CYP1A2—Metabolism—GNAS—peripheral nervous system neoplasm	1.98e-06	0.000217	CbGpPWpGaD
Buprenorphine—CYP1A2—Metabolism—ABCB1—peripheral nervous system neoplasm	1.94e-06	0.000213	CbGpPWpGaD
Buprenorphine—OPRD1—Signaling Pathways—TP53—peripheral nervous system neoplasm	1.91e-06	0.000209	CbGpPWpGaD
Buprenorphine—CYP3A4—Metabolism—SLC2A1—peripheral nervous system neoplasm	1.9e-06	0.000208	CbGpPWpGaD
Buprenorphine—CYP3A4—Metabolism—TH—peripheral nervous system neoplasm	1.87e-06	0.000205	CbGpPWpGaD
Buprenorphine—OPRM1—Signaling Pathways—NRAS—peripheral nervous system neoplasm	1.85e-06	0.000202	CbGpPWpGaD
Buprenorphine—CYP2C18—Metabolism—AKT1—peripheral nervous system neoplasm	1.85e-06	0.000202	CbGpPWpGaD
Buprenorphine—OPRD1—Signaling Pathways—HRAS—peripheral nervous system neoplasm	1.82e-06	0.0002	CbGpPWpGaD
Buprenorphine—OPRM1—Signaling Pathways—MYC—peripheral nervous system neoplasm	1.72e-06	0.000188	CbGpPWpGaD
Buprenorphine—OPRK1—Signaling Pathways—TP53—peripheral nervous system neoplasm	1.67e-06	0.000183	CbGpPWpGaD
Buprenorphine—OPRD1—Signaling Pathways—AKT1—peripheral nervous system neoplasm	1.61e-06	0.000176	CbGpPWpGaD
Buprenorphine—OPRK1—Signaling Pathways—HRAS—peripheral nervous system neoplasm	1.6e-06	0.000175	CbGpPWpGaD
Buprenorphine—CYP3A4—Metabolism—GNAS—peripheral nervous system neoplasm	1.53e-06	0.000167	CbGpPWpGaD
Buprenorphine—CYP3A4—Metabolism—ABCB1—peripheral nervous system neoplasm	1.5e-06	0.000164	CbGpPWpGaD
Buprenorphine—UGT1A9—Metabolism—AKT1—peripheral nervous system neoplasm	1.46e-06	0.00016	CbGpPWpGaD
Buprenorphine—OPRM1—Signaling Pathways—TP53—peripheral nervous system neoplasm	1.41e-06	0.000155	CbGpPWpGaD
Buprenorphine—OPRK1—Signaling Pathways—AKT1—peripheral nervous system neoplasm	1.41e-06	0.000155	CbGpPWpGaD
Buprenorphine—OPRM1—Signaling Pathways—HRAS—peripheral nervous system neoplasm	1.35e-06	0.000148	CbGpPWpGaD
Buprenorphine—ABCG2—Metabolism—AKT1—peripheral nervous system neoplasm	1.24e-06	0.000136	CbGpPWpGaD
Buprenorphine—CYP3A7—Metabolism—AKT1—peripheral nervous system neoplasm	1.23e-06	0.000134	CbGpPWpGaD
Buprenorphine—OPRM1—Signaling Pathways—AKT1—peripheral nervous system neoplasm	1.19e-06	0.000131	CbGpPWpGaD
Buprenorphine—CYP2A6—Metabolism—AKT1—peripheral nervous system neoplasm	1.13e-06	0.000123	CbGpPWpGaD
Buprenorphine—CYP3A5—Metabolism—AKT1—peripheral nervous system neoplasm	8.88e-07	9.71e-05	CbGpPWpGaD
Buprenorphine—CYP2C8—Metabolism—AKT1—peripheral nervous system neoplasm	7.69e-07	8.41e-05	CbGpPWpGaD
Buprenorphine—CYP2C19—Metabolism—AKT1—peripheral nervous system neoplasm	6.86e-07	7.51e-05	CbGpPWpGaD
Buprenorphine—ABCB1—Metabolism—AKT1—peripheral nervous system neoplasm	6.7e-07	7.33e-05	CbGpPWpGaD
Buprenorphine—CYP2D6—Metabolism—AKT1—peripheral nervous system neoplasm	6.31e-07	6.91e-05	CbGpPWpGaD
Buprenorphine—CYP2C9—Metabolism—AKT1—peripheral nervous system neoplasm	6.26e-07	6.85e-05	CbGpPWpGaD
Buprenorphine—CYP1A2—Metabolism—AKT1—peripheral nervous system neoplasm	5.35e-07	5.85e-05	CbGpPWpGaD
Buprenorphine—CYP3A4—Metabolism—AKT1—peripheral nervous system neoplasm	4.13e-07	4.52e-05	CbGpPWpGaD
